2016
Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study
Kunin-Batson AS, Lu X, Balsamo L, Graber K, Devidas M, Hunger SP, Carroll WL, Winick NJ, Mattano LA, Maloney KW, Kadan-Lottick NS. Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study. Cancer 2016, 122: 1608-1617. PMID: 27028090, PMCID: PMC4860039, DOI: 10.1002/cncr.29946.Peer-Reviewed Original ResearchConceptsAcute lymphoblastic leukemiaCompletion of treatmentGreater riskEmotional-behavioral functioningChildren's Oncology Group protocolsChildhood acute lymphoblastic leukemiaAdjusted longitudinal analysesCompletion of chemotherapyDepressive symptoms 6 monthsSymptoms 6 monthsEmotional distressElevated anxiety scoresAnxiety 1 monthStandardized rating scalesElevated depression scoresChildren's emotional-behavioral functioningLymphoblastic leukemiaPredictors of anxietySocial support copingMeasures of copingDepressive symptomsGeneral populationDepression scoresPsychosocial interventionsEarly screening
2014
Family life events in the first year of acute lymphoblastic leukemia therapy: A children's oncology group report
Lau S, Lu X, Balsamo L, Devidas M, Winick N, Hunger SP, Carroll W, Stork L, Maloney K, Kadan‐Lottick N. Family life events in the first year of acute lymphoblastic leukemia therapy: A children's oncology group report. Pediatric Blood & Cancer 2014, 61: 2277-2284. PMID: 25175168, PMCID: PMC4282930, DOI: 10.1002/pbc.25195.Peer-Reviewed Original ResearchConceptsAcute lymphoblastic leukemiaChildren's Oncology Group reportChildhood acute lymphoblastic leukemiaAcute lymphoblastic leukemia therapyMonths of therapyProspective cohort studyAppropriate anticipatory guidanceHigh cure ratesLong-term outcomesMore childrenHealth care providersLess maternal educationFirst yearCohort studyPatient factorsCure rateLymphoblastic leukemiaCOG protocolsCare providersAnticipatory guidanceEligibility criteriaHigh incidenceLeukemia therapyMaternal educationAverage risk